CordenPharma in peptide expansion
CordenPharma has announced the addition of a 3,000-litre solid-phase peptide synthesis (SPPS) vessel at its GMP API facility in Boulder, Colorado. This site, which was formerly owned by Roche, already has a 10,000-litre SPPS vessel and a 100 cm high-pressure reverse phase purification column, and is claimed to have the largest capacity of any peptide API facility.
The investment was made in response to what the company called “a large spike in the demand for peptide APIs, and to continue an overall growth strategy”. The vessel will enable it to manufacture a complex long peptide with a 400 kg output per single batch, according to Dr Matthieu Giraud, director of the Global Peptides, Lipids & Carbohydrates platform.
RELATED ARTICLES
Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4.
Jubilant Ingrevia has commissioned a new 2,000 tonnes/year facility for diketene derivatives at Gajraula in India’s Uttar Pradesh state. The company’s supplies these to the pharmaceuticals, agrochemicals and other industries, including the US and the EU.
EuroAPI has suspended all API production at its site in Brindisi, Italy, until further notice. This followed an internal audit in which “quality control deficiencies due to potential local misconduct” were identified. These are being further investigated.
W.R. Grace has formally opened an expansion of the pharmaceutical CDMO expansion project it began 21 months ago at its site in South Haven, Michigan.
Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.
Noramco, an API supplier specialised in controlled substances, has launched Noramco Group, which it describes as a “comprehensive North American-based supply chain solution” for clinical and commercial APIs and drug products. Noramco Group unites the capabilities of three subsidiaries:
